Pfizer's experimental drug misses main goal of lung cancer trial
Pfizer said on Monday its drug for a type of lung cancer missed the main goal of a late-stage trial.
PFE - Pfizer Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$26.75
DETAILS
HIGH:
$30.00
LOW:
$25.00
MEDIAN:
$27.00
CONSENSUS:
$26.75
UPSIDE:
6.66%
Stock News
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvo.
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry.
Pfizer Stock Edges Lower Monday: What's Going On?
Pfizer Inc. (NYSE:PFE) shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat. Here's what investors need to know.
Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead
Pfizer has leaned on acquisitions in recent years to strengthen its growth prospects. Acquisitions, however, can add costs and lead to inefficiency.
Could Pfizer Stock Be Your Ticket to Generational Wealth?
Pfizer is one of the world's most respected pharmaceutical companies. Pfizer is working through a normal product cycle in the drug sector.
Own 500 Shares of Pfizer and JNJ and Here's Your Annual Dividend Income
Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week.
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
Eli Lilly is a market darling because it is a leader in the GLP-1 weight-loss market. Pfizer hasn't even entered the GLP-1 race yet, which is one reason why its shares are comparatively unloved.
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.
Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook
Expand NYSE: PFE Pfizer Today's Change (-2.57%) $-0.67 Current Price $25.25 Key Data Points Market Cap $148B Day's Range $24.95 - $25.66 52wk Range $23.11 - $28.75 Volume 2.7M Avg Vol 36.2M Gross Margin 65.16% Dividend Yield 6.64% Pfizer (PFE 2.57%), a large-cap biopharmaceutical company focused on medicines, vaccines, and specialty therapeutics, closed at $25.21, down 2.74%. This morning's CFO transition announcement and succession review kept investors focused on 2026 guidance and leadership continuity.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Pfizer (PFE) reached $25.22 at the closing of the latest trading day, reflecting a -2.72% change compared to its last close.
Pfizer Stock Drops Today As CFO Steps Down In August
Pfizer Inc. (NYSE:PFE) shares are slipping Thursday after the company announced that Chief Financial Officer Dave Denton will leave the organization. Here's what you need to know.
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.
Pfizer CFO Dave Denton to step down, leave company in August
Pfizer said on Thursday that finance chief Dave Denton will step down and leave the company on August 15 to take a role in the consumer goods industry.
Pfizer Announces Chief Financial Officer Transition
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehens.
Pfizer: Why I'm Still Expecting A Massive Rebound
Pfizer Inc. remains a Buy with 55%+ upside potential over two years, driven by a robust pipeline and undervalued forward earnings. PFE's Q1 2026 results beat estimates, with non-COVID sales up 7% YoY and strong contributions from Seagen and new product launches. Key catalysts include the potential blockbuster GLP-1 candidate berobenatide, aggressive oncology growth, and patent settlements extending revenue streams.
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again.
Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
Pfizer's business may be in better shape than investors think.
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Price Targets
UBS Reiterates Neutral Rating on Pfizer (PFE)
$27.00
(was $26.34)
Michael Yee
·
UBS
Pfizer price target raised to $26 from $25 at Wolfe Research
$26.00
(was $25.96)
Alexandria Hammond
·
Wolfe Research
Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive'
$27.00
(was $27.05)
Terence Flynn
·
Morgan Stanley
BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data
$30.00
(was $26.48)
Evan David Seigerman
·
BMO Capital
RBC Capital Starts Pfizer (PFE) at Underperform
$25.00
(was $27.14)
Trung Huynh
·
RBC Capital
Pfizer initiated with an Underweight at Barclays
$25.00
(was $26.86)
Emily Field
·
Barclays
Pfizer downgraded to Neutral from Outperform at Daiwa
$27.00
(was $27.73)
Narumi Nakagiri
·
Daiwa
Pfizer price target raised to $27 from $24 at Cantor Fitzgerald
$27.00
(was $25.88)
Cantor Fitzgerald
Pfizer assumed with a Neutral at UBS
$25.00
(was $25.43)
UBS
Pfizer (PFE) PT Lowered to $24 at Wolfe Research
$24.00
(was $25.53)
Alexandria Hammond
·
Wolfe Research
Pfizer price target lowered to $28 from $32 at Morgan Stanley
$28.00
(was $25.89)
Morgan Stanley
Pfizer price target raised to $29 from $28 at HSBC
$29.00
(was $25.33)
Rajesh Kumar
·
HSBC
Pfizer price target raised to $35 from $33 at Guggenheim
$35.00
(was $25.17)
Guggenheim
Goldman Sachs on Pfizer (PFE): 'Challenging Crosscurrents As Focus Shifts To 2026 Guidance Next Month'
$26.00
(was $24.23)
Asad Haider
·
Goldman Sachs
Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera
$30.00
(was $24.45)
Courtney Breen
·
Bernstein
Pfizer price target lowered to $32 from $33 at Morgan Stanley
$32.00
(was $25.24)
Morgan Stanley
Pfizer drug pricing deal 'mostly performative,' says BofA
$28.00
(was $27.16)
Tim Anderson
·
UBS
Pfizer initiated with a Neutral at Cantor Fitzgerald
$24.00
(was $22.53)
Carter Gould
·
Cantor Fitzgerald
Pfizer price target lowered to $32 from $36 at Truist
$32.00
(was $25.89)
Robyn Karnauskas
·
Truist Financial
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
$33.00
(was $28.46)
Chris Shibutani
·
Goldman Sachs